Many Survivors Jobless After Respiratory Distress Syndrome

This article originally appeared here.
Share this content:
Many Survivors Jobless After Respiratory Distress Syndrome
Many Survivors Jobless After Respiratory Distress Syndrome

WEDNESDAY, May 3, 2017 (HealthDay News) -- Nearly half of previously employed acute respiratory distress syndrome (ARDS) survivors are jobless one year after hospital discharge, according to a study published online April 27 in the American Journal of Respiratory and Critical Care Medicine.

Biren B. Kamdar, M.D., M.B.A., M.H.S., from the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues examined the timing of return to work after ARDS during a 12-month longitudinal follow-up. Employment and health care coverage data were provided by ARDS survivors from 43 U.S. ARDSNet hospitals via telephone interviews.

The researchers found that 42 percent of the 922 consenting survivors were employed before ARDS, with seven dying by 12-month follow-up. At 12-month follow-up, 44 percent of 379 previously employed 12-month survivors were jobless. Half of enrolled and previously employed survivors returned to work by 13 weeks after hospital discharge after the researchers accounted for competing risks of death and retirement; 68 percent ever returned by 12 months. Among nonwhite survivors, delays in return to work correlated with longer hospitalization and older age. Seventy-one percent of survivors accrued lost earnings over 12-month follow-up, averaging $26,949 ± $22,447 (60 percent of pre-ARDS annual earnings). Jobless survivors experienced a 14 percent absolute decrease and a 16 percent absolute increase in private health insurance and Medicare and Medicaid, respectively.

"Post-ARDS joblessness is associated with readily identifiable patient and hospital variables, and accompanied by substantial lost earnings and a shift toward government-funded health care coverage," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »